Since April this year, Xinhua Pharmaceutical has experienced two rounds of speculation, and its share price has risen from 8 yuan to 46. 10 yuan/share? The increase was nearly five times, and the company's major shareholders and executives also took the opportunity to reduce their holdings.
COVID-19's oral medicine ursodeoxycholic acid and the recent ibuprofen made Xinhua Pharmaceutical stand at the forefront. It is conceivable that products such as ibuprofen will bring considerable benefits to Xinhua Pharmaceutical in the short term, but it is impossible to last.
The reporter of Changjiang Business Daily found that as an established pharmaceutical company, Xinhua Pharmaceutical is willing to chase hot spots. Previously, the company also dabbled in the concept of medical beauty. But the company's development is relatively slow. Since 20 13, Xinhua pharmaceutical has shown a stable profit state. But the company's net interest rate has been less than 6%.
It is worth mentioning that in recent years, Xinhua Pharmaceutical has been fined frequently for environmental problems.
The major shareholder was fined for cashing in nearly 100 million at a high position.
Since the beginning of this year, Xinhua Pharmaceutical has made a splash in the secondary market, which can be called unlimited scenery. However, this kind of scenery may not last long.
The K-line chart shows that the share price of Xinhua Pharmaceutical reached 8.07 yuan/share on April 13 this year. The previous year's stock price K line was in a flat state. On April 20 and 2 1 day, the stock price closed two daily limit boards. Then from April 26th to May 13, 1 1 daily limit board was closed at one breath. By May 30th, the share price climbed to 40.70 yuan/share.
This is the first round of skyrocketing, and the stock price rose from 8.07 yuan/share to 40.70 yuan/share, with a cumulative increase of 404.34%.
This increase is directly related to oral drugs in COVID-19.
On the evening of April 26th this year, Xinhua Pharmaceutical announced that on the same day, the company signed a strategic cooperation agreement with Henan Ruier Biotechnology Co., Ltd. (hereinafter referred to as "Ruier Bio"), and Ruier Bio agreed to be the manufacturer and distributor of the products owned by the company in China and other countries agreed by both parties.
The fact that afudin is called the oral specific drug in COVID-19 by the market has aroused widespread concern.
On the evening of May 1 1, Xinhua Pharmaceutical issued a risk warning announcement. The strategic cooperation agreement signed between the company and real creatures is based on the needs of the company's strategic development and the judgment of the industry market prospect. The future operating benefits of cooperative projects are uncertain. Xinhua Pharmaceutical specifically clarified that Aftab held by real organisms is an anti-AIDS drug, and the approval number of the State Medical and Drug Administration is 202 1. At present, the new clinical trial is anti-novel coronavirus indication. The clinical trial results of real biotherapy for this indication have not been released publicly, and the indication has not been approved by the State Administration of Medical Products.
In June, Xinhua Pharmaceutical's share price began to fall back, and fell back to around 16 yuan/share in late September this year, and then began to climb slightly.
Recently, the domestic epidemic prevention policy has been adjusted, and nucleic acid testing is no longer "tailored to the needs of inspection", and Xinhua Pharmaceutical has once again become a hot spot. 65438+February 5, Teresa of Cambridge University, UK? Brevini's research paper published in Nature shows that ursodeoxycholic acid or plant steroid Z-Guggulsterone can inhibit FXR signaling pathway and down-regulate the expression of ACE2, thus preventing COVID-19 infection. Ursodeoxycholic acid has the potential to be a preventive drug in COVID-19 and can be used as a supplement to vaccination.
Xinhua Pharmaceutical announced that Shandong Zibo Xinda Pharmaceutical Co., Ltd., a wholly-owned subsidiary of the company, obtained the qualification of marketing license holder of ursodeoxycholic acid tablets in June 2022. The clinical indication is to treat cholesterol gallstones, but it has not been commercialized.
With the increase of infected people, ibuprofen is hard to find. Xinhua pharmaceutical is on fire again. Because the company is an important supplier of ibuprofen.
12 16, Xinhua pharmaceutical said in reply to the inquiry that it is making every effort to organize the production of ibuprofen tablets, vitamin C tablets and other drugs urgently needed in the market.
12 16, Xinhua pharmaceutical's share price rose to 46. 10 yuan/share again, nearly five times higher than that in April this year.
The stock price has soared, and shareholders and executives can't sit still.
From 165438+ 10 to 14 this year, Lu Hua, the concerted action person of Lu Hua Holding Group, the controlling shareholder of Xinhua Pharmaceutical, reduced his holdings by 4 143200 shares and cashed in 99 million yuan.
165438+1On October 24th, Shenzhen Stock Exchange issued a supervision letter to Lu Hua for illegally reducing its holdings.
In addition, Chairman Zhang and Director Xu Lie, Deputy General Managers Wang Xiaolong, Du Deqing, Wei Changsheng and Xu Wenhui, Director and Deputy General Manager He Tongqing and Secretary Cao Changqiu collectively reduced their holdings of Xinhua Pharmaceutical within three days from July 27 to 29, 2022, with a total cash of about 6.707 million yuan.
The net interest rate in recent 20 years is less than 6%
The phenomenon that ibuprofen is hard to find is still there. By fully producing ibuprofen, Xinhua Pharmaceutical's operating performance is expected to increase substantially, but it may be difficult to sustain.
Xinhua Pharmaceutical was founded in 1943 with a history of 80 years. 1997 landed in the A-share market. The company is mainly engaged in the research and development, manufacturing and sales of chemical raw materials, preparations, pharmaceutical intermediates and other products. As a chemical synthesis of pharmaceuticals company, the company is an important global producer and export base of antipyretic and analgesic drugs, and also an important domestic manufacturer of cardiovascular and cerebrovascular diseases, anti-infective diseases and central nervous system drugs.
From the perspective of business performance, Xinhua Pharmaceutical is not outstanding. At the initial stage of listing, from 1997 to 200 1, the company realized operating income of 90160,000 yuan, 974 million yuan, 95 10/00,000 yuan, 1044 million yuan,1990,000 yuan respectively. The corresponding net profit attributable to shareholders of listed companies (referred to as net profit) is RMB 84 million, RMB 53 million, RMB 64 million, RMB 69 million and RMB 0.8 1 10,000 respectively, with obvious fluctuations. From 2002 to 2004, the operating income was1174 million yuan,132.8 million yuan and 15 1 100 million yuan respectively, increasing year by year. However, the corresponding net profits were 69 million yuan, 42 million yuan and-56 million yuan respectively, which decreased year by year. After listing in 2004, there was an annual loss for the first time.
From 2005 to 20 14, the operating income increased from169.7 billion yuan to 3.59 billion yuan, more than doubling. In terms of net profit, except for 2009, which broke through the billion yuan mark and reached 654.38+002 billion yuan, the rest of the years were less than 100 million yuan. After deducting non-recurring gains and losses, the annual net profit of 20 12 and 20 13 was-20 million yuan and-46 million yuan respectively, which was a loss for two consecutive years.
According to the data of net profit, it has increased for nine consecutive years from 20 13 to 202 1. Among them, the net profit from 20 17 to 202 1 was 2 10/00000 yuan, 25 10/000000 yuan, 300 million yuan, 325 million yuan and 349 million yuan respectively, up by 7 1.42% and/.
In the first three quarters of this year, the company achieved an operating income of 5.453 billion yuan, a year-on-year increase of 65.438+00.39%, and a net profit of 293 million yuan, a year-on-year increase of 2.84%.
Changjiang Business Daily reporter found that in the 20 years from 2002 to now, the highest gross profit margin of Xinhua Pharmaceutical appeared at 20 19, accounting for 33.44%. The corresponding net interest rate is 5.76%. In these 20 years, the company's net interest rate is less than 6%. In the pharmaceutical industry, such a net interest rate is obviously low.
In the 20021semi-annual report, Xinhua pharmaceutical once said that the company has been strictly abiding by national environmental protection policies and regulations, and will continue to increase investment in environmental protection and promote the upgrading of environmental protection facilities. Actively carry out safety and environmental protection training and education, strengthen enterprise internal control standards, strengthen monitoring of key pollution discharge points, reduce environmental risks, and achieve discharge standards.
However, Xinhua Pharmaceutical is often fined for environmental violations.
On June 29th this year, Xinhua Pharmaceutical was fined 12 10000 yuan by Zibo Municipal Bureau of Ecology and Environment because the sewage outlet was not included in the management of sewage discharge permit. On February 9th, Xinhua Pharmaceutical was fined 6,543,800 yuan+0,320 yuan by Zibo Municipal Bureau of Ecology and Environment because the way and direction of sewage discharge did not conform to the sewage discharge permit.
In addition, on June 26th, 65438+,Zibo Municipal Bureau of Ecology and Environment fined Shandong Xinhua Wanbo Chemical Co., Ltd., a wholly-owned subsidiary of Xinhua Pharmaceutical Co., Ltd., on the grounds that the company failed to limit the discharge of pollutants in autumn and winter of 20265438+. On February 10, Zibo Xinhua-Bailigao Pharmaceutical, a holding subsidiary of Xinhua Pharmaceutical, was fined 819,000 yuan for environmental violations of Company 20211.
In recent years, although the operating performance of Xinhua Pharmaceutical has grown slowly, it is still stable, but is this related to the sacrifice of environmental protection?